Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide- intermediate Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 3, 2012, Pages 1476-1484

  Fernandez, Jeffrey ^a   Abbanat, Darren ^a   Shang, Wenchi ^a   He, Wenping ^a   Amsler, Karen ^a   Hastings, James ^a   Queenan, Anne Marie ^a   Melton, John L ^a   Barron, Alfred M ^a   Flamm, Robert K ^a,b   Lynch, A Simon ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b JMI LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTOBIPROLE; CEFTOBIPROLE MEDOCARIL; DAPTOMYCIN; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL CELL; BACTERIAL ENDOCARDITIS; BACTERIAL STRAIN; BLOOD SAMPLING; BODY WEIGHT; CELL DENSITY; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; GLYCOPEPTIDE INTERMEDIATE STAPHYLOCOCCUS AUREUS; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RAT; STAPHYLOCOCCUS;

ANIMALS; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; DAPTOMYCIN; DRUG DOSAGE CALCULATIONS; DRUG SYNERGISM; ENDOCARDITIS, BACTERIAL; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; RATS; RATS, SPRAGUE-DAWLEY; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 84857163362     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06057-11     Document Type: Article

References (71)

1. Barr JG, Smyth ET, Hogg GM. 1990. In vitro antimicrobial activity of imipenem in combination with vancomycin or teicoplanin against Staphylococcus aureus and Staphylococcus epidermidis. Eur. J. Clin. Microbiol. Infect. Dis. 9:804-809.
2. Bogdanovich T, Ednie LM, Shapiro S, Appelbaum PC. 2005. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob. Agents Chemother. 49:4210-4219. (Pubitemid 41400966)
3. Borbone S, Campanile F, Bongiorno D, Stefani S. 2010. In vitro bactericidal activity of ceftobiprole against hospital- and community-associated methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 65:591-594.
4. Bozdogan B, Esel D, Whitener C, Browne FA, Appelbaum PC. 2003. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J. Antimicrob. Chemother. 52:864-868. (Pubitemid 37407819)
5. Catherall EJ, Gillon V, Hurn S, Irwin R, Mizen L. 1992. Efficacy of ticarcillin-clavulanic acid for treatment of experimental Staphylococcus aureus endocarditis in rats. Antimicrob. Agents Chemother. 36:458-462.
6. Chadwick EG, Shulman ST, Yogev R. 1986. Correlation of antibiotic synergy in vitro and in vivo: use of an animal model of neutropenic gram-negative sepsis. J. Infect. Dis. 154:670-675. (Pubitemid 16032416)
7. Chambers HF. 2005. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycinintermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 49:884-888. (Pubitemid 40327700)
8. Chang S, et al. 2003. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N. Engl. J. Med. 348:1342-1347. (Pubitemid 36384101)
9. Chung M, Antignac A, Kim C, Tomasz A. 2008. Comparative study of the susceptibilities of major epidemic clones of methicillin-resistant Staphylococcus aureus to oxacillin and to the new broad-spectrum cephalosporin ceftobiprole. Antimicrob. Agents Chemother. 52:2709-2717.
10. CLSI/NCCLS. 1999. Methods for determining bacterial activity of antimicrobial agents; approved guideline. CLSI/NCCLS document M26-A. Clinical and Laboratory Standards Institute, Wayne, PA.
11. CLSI. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, eighth edition. CLSI document M07-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
12. CLSI. 2010. Performance standards for antimicrobial susceptibility testing; 20th informational supplement. CLSI document M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA.
13. Cooper MA, Shlaes D. 2011. Fix the antibiotics pipeline. Nature 472:32.
14. Deresinski S. 2007. Counterpoint: vancomycin and Staphylococcus aureus - an antibiotic enters obsolescence. Clin. Infect. Dis. 44:1543-1548. (Pubitemid 46871499)
15. Deresinski S. 2009. Vancomycin in combination with other antibiotics for the treatment of serious methicillin-resistant Staphylococcus aureus infections. Clin. Infect. Dis. 49:1072-1079.
16. Deresinski S. 2007. Vancomycin: does it still have a role as an antistaphylococcal agent? Expert Rev. Anti Infect. Ther. 5:393-401. (Pubitemid 47050161)
17. Deshpande LM, Jones RN. 2003. Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococci. Clin. Microbiol. Infect. 9:1120-1124. (Pubitemid 37428051)
18. Donabedian H, Andriole VT. 1977. Synergy of vancomycin with penicillins and cephalosporins against Pseudomonas, Klebsiella, and Serratia. Yale J. Biol. Med. 50:165-176. (Pubitemid 8137328)
19. Dworkin R, et al. 1990. Comparative efficacies of ciprofloxacin, pefloxacin, and vancomycin in combination with rifampin in a rat model of methicillin-resistant Staphylococcus aureus chronic osteomyelitis. Antimicrob. Agents Chemother. 34:1014-1016. (Pubitemid 20177345)
20. Eagle H. 1948. A paradoxical zone phenomenon in the bactericidal action of penicillin in vitro. Science 107:44-45.
21. Eagle H, Musselman AD. 1948. The rate of bactericidal action of penicillin in vitro as a function of its concentration, and its paradoxically reduced activity at high concentrations against certain organisms. J. Exp. Med. 88:99-131.
22. Entenza JM, Hohl P, Heinze-Krauss I, Glauser MP, Moreillon P. 2002. BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis. Antimicrob. Agents Chemother. 46:171-177. (Pubitemid 34031620)
23. Entenza JM, et al. 2011. In vivo synergism of ceftobiprole and vancomycin against experimental endocarditis due to vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 55:3977-3984.
24. Entenza JM, et al. 2010. In vitro synergism between ceftobiprole and vancomycin against methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus, abstr O-39. Abstr. 20th Eur. Congr. Clin. Microbiol. Infect. Dis. (ECCMID).
25. Fantin B, Carbon C. 1992. In vivo antibiotic synergism: contribution of animal models. Antimicrob. Agents Chemother. 36:907-912.
26. Fernandez J, et al. 2010. Efficacy of ceftobiprole (BPR) alone and in combination with vancomycin (VAN) in a rat MRSA infective endocarditis (IE) model, abstr B-061. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., Boston, MA.
27. Geisel R, Schmitz FJ, Fluit AC, Labischinski H. 2001. Emergence, mechanism, and clinical implications of reduced glycopeptide susceptibility in Staphylococcus aureus. Eur. J. Clin. Microbiol. Infect. Dis. 20:685-697. (Pubitemid 33020779)
28. Gemmell CG. 2004. Glycopeptide resistance in Staphylococcus aureus: is it a real threat? J. Infect. Chemother. 10:69-75. (Pubitemid 38590728)
29. Gentry CA, Rodvold KA, Novak RM, Hershow RC, Naderer OJ. 1997. Retrospective evaluation of therapies for Staphylococcus aureus endocarditis. Pharmacotherapy 17:990-997. (Pubitemid 27415102)
30. Goldstein FW, Kitzis MD. 2003. Vancomycin-resistant Staphylococcus aureus: no apocalypse now. Clin. Microbiol. Infect. 9:761-765. (Pubitemid 37121077)
31. Hamilton-Miller JM. 1971. The demonstration and significance of synergism between β-lactam antibiotics. J. Med. Microbiol. 4:227-237.
32. Hiramatsu K. 2001. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect. Dis. 1:147-155. (Pubitemid 33586048)
33. Hiramatsu K, et al. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:135-136. (Pubitemid 27341646)
34. Hollander M, Wolfe DW. 1999. Nonparametric statistical methods, 2nd ed. John Wiley & Sons, New York, NY.
35. Horstkotte D, et al. 2004. Guidelines on prevention, diagnosis and treatment of infective endocarditis executive summary: The Task Force on Infective Endocarditis of the European Society of Cardiology. Eur. Heart J. 25:267-276. (Pubitemid 38235165)
36. Jewetz E, Gunnison JB, Bruff JB, Coleman VR. 1952. Studies on antibiotic synergism and antagonism. Synergism among seven antibiotics against various bacteria in vitro. J. Bacteriol. 64:29-39.
37. Johnson & Johnson Pharmaceutical Research and Development. 2009. Ceftobiprole investigators brochure. Johnson & Johnson Pharmaceutical Research and Development L.L.C., Raritan, NJ.
38. Kusama M, et al. 1998. Effect of cilastatin on renal handling of vancomycin in rats. J. Pharm. Sci. 87:1173-1176. (Pubitemid 28452122)
39. LaPlante KL, Rybak MJ. 2004. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 48:4665-4672. (Pubitemid 39577670)
40. Leonard SN, Cheung CM, Rybak MJ. 2008. Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 52:2974-2976.
41. Levine DP. 2008. Vancomycin: understanding its past and preserving its future. South. Med. J. 101:284-291. (Pubitemid 351499282)
42. Lin G, Appelbaum PC. 2008. Activity of ceftobiprole compared with those of other agents against Staphylococcus aureus strains with different resistotypes by time-kill analysis. Diagn. Microbiol. Infect. Dis. 60:233-235.
43. Linares J. 2001. The VISA/GISA problem: therapeutic implications. Clin. Microbiol. Infect. 7(Suppl. 4):8-15. (Pubitemid 34966103)
44. Liu C, Chambers HF. 2003. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob. Agents Chemother. 47: 3040-3045. (Pubitemid 37229554)
45. Lodise TP, et al. 2008. Pharmacokinetic and pharmacodynamic profile of ceftobiprole. Diagn. Microbiol. Infect. Dis. 61:96-102. (Pubitemid 351509756)
46. Lowy FD. 2003. Antimicrobial resistance: the example of Staphylococcus aureus. J. Clin. Invest. 111:1265-1273. (Pubitemid 36554694)
47. Moody J. 2010. Synergism testing: broth microdilution checkerboard and broth macrodilution methods, p 5.12.1-5.12.23. InGarcia L (ed), Clinical microbiology procedures handbook, 3rd ed, vol 2. ASM Press, Washington, DC.
48. Moore MR, Perdreau-Remington F, Chambers HF. 2003. Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis. Antimicrob. Agents Chemother. 47: 1262-1266. (Pubitemid 36368583)
49. Murillo O, et al. 2006. Efficacy of high doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus. Antimicrob. Agents Chemother. 50:4011-4017. (Pubitemid 44865143)
50. Murphy TM, Deitz JM, Petersen PJ, Mikels SM, Weiss WJ. 2000. Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis. Antimicrob. Agents Chemother. 44:3022-3027.
51. Murthy B, Schmitt-Hoffmann A. 2008. Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity. Clin. Pharmacokinet. 47:21-33. (Pubitemid 350260886)
52. NCCLS. 1999. Methods for determining bactericidal activity of antimicrobial agents; approved guidelines M26-A. NCCLS/Clinical and Laboratory Standards Institute, Wayne, PA.
53. Pelletier LL, Jr. 2010. Infective endocarditis. The Merck manual for health care professionals. Merck Sharps & Dohme Corp., Whitehouse Station, NJ. http://www.merckmanuals.com/professional/print/cardiovascular -disorders/endocarditis/infective-endocarditis.html.
54. Pienaar E, Whitney SE, Viljoen HJ, van Rensburg NFJ. 2009. A model of the complex response of Staphylococcus aureus to methicillin. J. Theor. Biol. 257:438-445.
55. Rose WE, Poppens PT. 2009. Impact of biofilm on the in vitro activity of vancomycin alone and in combination with tigecycline and rifampicin against Staphylococcus aureus. J. Antimicrob. Chemother. 63:485-488.
56. Sakoulas G, Eliopoulos GM, Alder J, Eliopoulos CT. 2003. Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 47:1714-1718. (Pubitemid 36548559)
57. Sauermann R, Rothenburger M, Graninger W, Joukhadar C. 2008. Daptomycin: a review 4 years after first approval. Pharmacology 81: 79-91. (Pubitemid 351182681)
58. Sieradzki K, Tomasz A. 1997. Suppression of beta-lactam antibiotic resistance in a methicillin-resistant Staphylococcus aureus through synergic action of early cell wall inhibitors and some other antibiotics. J. Antimicrob. Chemother. 39(Suppl. A):47-51. (Pubitemid 27281499)
59. Small PM, Chambers HF. 1990. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob. Agents Chemother. 34:1227-1231. (Pubitemid 20177385)
60. Tabaqchali S. 1997. Vancomycin-resistant Staphylococcus aureus: apocalypse now? Lancet 350:1644-1645. (Pubitemid 28036820)
61. Tattevin P, Basuino L, Bauer D, Diep BA, Chambers HF. 2010. Ceftobiprole is superior to vancomycin, daptomycin, and linezolid for treatment of experimental endocarditis in rabbits caused by methicillinresistant Staphylococcus aureus. Antimicrob. Agents Chemother. 54:610-613.
62. Tenover FC, Biddle JW, Lancaster MV. 2001. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg. Infect. Dis. 7:327-332. (Pubitemid 32374355)
63. Totsuka K, Shiseki M, Kikuchi K, Matsui Y. 1999. Combined effects of vancomycin and imipenem against methicillin-resistant Staphylococcus aureus (MRSA) in vitro and in vivo. J. Antimicrob. Chemother. 44:455-460. (Pubitemid 29490614)
64. Vouillamoz J, Entenza JM, Veloso TR, Giddey M, Moreillon P. 2010. In vivo synergism of ceftobiprole in combination with vancomycin against experimental endocarditis due to vancomycin-intermediate Staphylococcus aureus, abstr B-062. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., Boston, MA.
65. Walsh TR, Howe RA. 2002. The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus. Annu. Rev. Microbiol. 56:657-675. (Pubitemid 35217470)
66. Westfall PH, Tobias RD, Rom D, Wolfinger RD, Hochberg Y. 1999. Multiple comparisons and multiple tests using the SAS system. SAS Institute Inc., Cary NC.
67. White RL, Burgess DS, Manduru M, Bosso JA. 1996. Comparison of three different in vitro methods of detecting synergy: time-kill, checker-board, and E test. Antimicrob. Agents Chemother. 40:1914-1918. (Pubitemid 26277815)
68. Whitener CJ, et al. 2004. Vancomycin-resistant Staphylococcus aureus in the absence of vancomycin exposure. Clin. Infect. Dis. 38:1049- 1055.
69. Xiong YQ, et al. 2009. Efficacy of ceftobiprole, a novel cephalosporin antibiotic, in a rat Staphylococcus aureus endocarditis (IE) model: microbiological and real-time bioluminescent assessments, abstr B-054. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA.
70. Xiong YQ, et al. 2005. Real-time in vivo bioluminescent imaging for evaluating the efficacy of antibiotics in a rat Staphylococcus aureus endocarditis model. Antimicrob. Agents Chemother. 49:380-387. (Pubitemid 40065815)
71. Zhanel GG, et al. 2009. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model. J. Antimicrob. Chemother. 64:364-369.